Xilio Therapeutics granted stock options to new employees under Inducement Stock Incentive Plan.

From GlobeNewswire: 2025-04-04 16:30:00

Xilio Therapeutics, Inc. granted non-qualified stock options to three new employees on April 1, 2025, totaling 22,900 shares of common stock. The stock options have an exercise price of $0.7244 per share and will vest over a ten-year term. The options were granted under the company’s 2022 Inducement Stock Incentive Plan. Xilio Therapeutics focuses on developing tumor-activated immuno-oncology therapies to improve cancer outcomes. The company’s goal is to localize anti-tumor activity within the tumor microenvironment, reducing systemic side effects. For more information, visit www.xiliotx.com and follow Xilio Therapeutics, Inc. on LinkedIn. Contact Scott Young for investor or media inquiries at [email protected].



Read more at GlobeNewswire: Xilio Therapeutics Announces Inducement Grants Under Nasdaq